Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Boehringer Ingelheim
Harvard Business School
Mallinckrodt
AstraZeneca

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,611,724

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,611,724 protect, and when does it expire?

Patent 7,611,724 protects ISTODAX and is included in one NDA.

This patent has five patent family members in five countries.

Summary for Patent: 7,611,724
Title:Method of producing FR901228
Abstract:Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion. Also provided are crystalline forms of FR901228, e.g., type A and type B crystalline forms of FR901228.
Inventor(s): Ueda; Satoshi (Chuo-ku, JP), Watamoto; Yoko (Chuo-ku, JP), Tsuboi; Masaru (Chuo-ku, JP), Kanda; Munekazu (Chuo-ku, JP), Higaki; Tomoji (Chuo-ku, JP), Matsuda; Mitsunori (Chuo-ku, JP)
Assignee: Astellas Pharma Inc. (Tokyo, JP)
Application Number:12/396,773
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,611,724
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 7,611,724

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Celgene ISTODAX romidepsin POWDER;INTRAVENOUS 022393-001 Nov 5, 2009 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,611,724

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2000-265414Sep 01, 2000

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
AstraZeneca
Johnson and Johnson
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.